This biotechnology company specializes in the development of Glunozumab, a monoclonal antibody with a unique mechanism of action. By hyperactivating both vascular and neuronal NMDA receptors, Glunozumab disrupts the blood-brain and blood-spinal cord barriers, leading to severe neuronal excitotoxicity. This groundbreaking drug has the potential to address conditions such as stroke and multiple sclerosis, offering new hope for patients suffering from these debilitating disorders.